PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för bictegravir. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

27 hits

Bibliografisk träff 2021-10-01

Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).

Imaz A, Tiraboschi JM, Niubó J, Martinez-Picado J, Cottrell ML, Domingo P, Chivite I, Negredo E, Schauer A, Van Horne B, Morenilla S, Urrea V, Silva-Klug A, Scévola S, Garcia B, Kashuba ADM, Podzamczer D.

Clin Infect Dis · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1093/cid/ciaa1416

Bibliografisk träff 2021-07-01

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.

Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H, GS-US-380–4030 Investigators.

Clin Infect Dis · equivalence trial; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/cid/ciaa988

Bibliografisk träff 2021-07-01

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.

Acosta RK, Chen GQ, Chang S, Martin R, Wang X, Huang H, Brainard D, Collins SE, Martin H, White KL.

J Antimicrob Chemother · clinical trial, phase iii; research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkab115

Bibliografisk träff 2021-06-01

Lack of clinically relevant interactions between bictegravir and metformin in persons with diabetes and HIV.

Cattaneo D, Formenti T, Minisci D, Casalini G, Meraviglia P, Gervasoni C.

J Antimicrob Chemother · letter · DOI 10.1093/jac/dkab077

Bibliografisk träff 2021-05-11

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV.

Chen IW, Sun HY, Hung CC.

Infect Dis Ther · research-article; journal article · DOI 10.1007/s40121-021-00449-z

Bibliografisk träff 2021-03-29

Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.

Stader F, Battegay M, Marzolini C.

Clin Pharmacol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cpt.2221

Bibliografisk träff 2021-03-18

A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.

Mandal S, Prathipati PK, Sunagawa SW, Destache CJ.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.02320-20

Bibliografisk träff 2021-03-09

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J.

Infect Dis Ther · research-article; journal article · DOI 10.1007/s40121-021-00419-5

Bibliografisk träff 2021-03-01

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.

White KL, Osman N, Cuadra-Foy E, Brenner BG, Shivakumar D, Campigotto F, Tsiang M, Morganelli PA, Novikov N, Lazerwith SE, Jin H, Niedziela-Majka A.

Antimicrob Agents Chemother · brief-report; journal article · DOI 10.1128/aac.02406-20

Bibliografisk träff 2021-02-27

Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.

Stader F, Courlet P, Decosterd LA, Battegay M, Marzolini C.

Clin Pharmacol Ther · brief-report; clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1002/cpt.2178

Bibliografisk träff 2021-02-01

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.

Bekerman E, Cox S, Babusis D, Campigotto F, Das M, Barouch DH, Cihlar T, Callebaut C.

J Antimicrob Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/jac/dkaa476

Bibliografisk träff 2020-12-30

Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.

Baldin G, Ciccullo A, Lombardi F, D'Angelillo A, Dusina A, Emiliozzi A, Farinacci D, Moschese D, Picarelli C, Borghetti A, Di Giambenedetto S.

AIDS Res Hum Retroviruses · journal article · DOI 10.1089/aid.2020.0219

Bibliografisk träff 2020-12-18

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments.

Perazzolo S, Mandal S, Prathipati PK, Destache CJ.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.603242

Bibliografisk träff 2020-12-18

Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.

Schafer JJ, Pandit NS, Cha A, Huesgen E, Badowski M, Sherman EM, Cocohoba J, Shimada A, Keith SW.

Open Forum Infect Dis · research-article; journal article · DOI 10.1093/ofid/ofaa625

Bibliografisk träff 2020-11-01

Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.

Pencolé L, Lê MP, Bouchet-Crivat F, Duro D, Peytavin G, Mandelbrot L.

AIDS · research support, non-u.s. gov't; journal article · DOI 10.1097/qad.0000000000002637

Bibliografisk träff 2020-11-01

Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir.

Soudeyns H, Dumond J.

AIDS · comment; journal article · DOI 10.1097/qad.0000000000002634

Bibliografisk träff 2020-10-20

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Gelé T, Gouget H, Furlan V, Becker PH, Taburet AM, Lambotte O, Barrail-Tran A.

Antimicrob Agents Chemother · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1128/aac.00895-20

Bibliografisk träff 2020-08-29

Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.

Ferrández JS, García AL, Alonso-Vega GG, González AO, García TM.

Ann Pharmacother · letter; case reports · DOI 10.1177/1060028020953631

Bibliografisk träff 2020-07-21

Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.

Riva A, Cattaneo D, Filice C, Gervasoni C.

Int J STD AIDS · journal article; case reports · DOI 10.1177/0956462420934981

Bibliografisk träff 2020-07-04

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir.

Rock AE, DeMarais PL, Vergara-Rodriguez PT, Max BE.

Infect Dis Ther · review-article; review; journal article · DOI 10.1007/s40121-020-00307-4

Bibliografisk träff 2020-02-10

Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.

Biagi MJ, Schriever CA, Chiampas TD, Michienzi SM, Michienzi SM, Patel MC, Young JD, Badowski ME.

Int J STD AIDS · journal article; case reports · DOI 10.1177/0956462419895665

Bibliografisk träff 2020-01-30

Structural basis for strand-transfer inhibitor binding to HIV intasomes.

Passos DO, Li M, Jóźwik IK, Zhao XZ, Santos-Martins D, Yang R, Smith SJ, Jeon Y, Forli S, Hughes SH, Burke TR, Craigie R, Lyumkis D.

Science · research support, n.i.h., intramural; research-article; journal article; research support, n.i.h., extramural · DOI 10.1126/science.aay8015

Bibliografisk träff 2020-01-30

Structural basis of second-generation HIV integrase inhibitor action and viral resistance.

Cook NJ, Li W, Berta D, Badaoui M, Ballandras-Colas A, Nans A, Kotecha A, Rosta E, Engelman AN, Cherepanov P.

Science · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1126/science.aay4919

Bibliografisk träff 2019-11-01

Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.

Zeuli J, Rizza S, Bhatia R, Temesgen Z.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2019.55.11.3068796

Bibliografisk träff 2018-07-01

Bictegravir.

Spagnuolo V, Castagna A, Lazzarin A.

Curr Opin HIV AIDS · review; journal article · DOI 10.1097/coh.0000000000000468

Bibliografisk träff 2017-05-01

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.

Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H, White K, Cheng A, Quirk E, Martin H.

J Acquir Immune Defic Syndr · research-article; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1097/qai.0000000000001306

Bibliografisk träff 2016-11-21

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.

Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.01474-16